BMS' AML drug Onureg gets push with NEJM publication

5 January 2021

Onureg (azacytidine tablets), the Bristol Myers Squibb (NYSE: BMY) drug approved in the USA last year for the continued treatment of patients in first complete remission with acute myeloid leukemia (AML), has been given an airing in the New England Journal of Medicine (NEJM).

Data has been published in the NEJM from the Phase III QUAZAR AML-001 study, which showed Onureg doubled relapse-free survival versus placebo in patients with AML in the maintenance setting.

AML is one of the most common acute leukemias in adults. While most patients achieve remission following initial treatment, approximately 50% will relapse within one year. More options that prolong overall survival and reduce the risk of relapse are needed for those living with this aggressive and persistent blood cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK